A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Resumo da notícia
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Acompanhe as notícias de fontes confiáveis com resumos breves. Abra o link original para ver os detalhes.